Kent William Mouw MD
Radiation Oncologist, Brigham & Women's Hospital/Dana-Farber Cancer Institute
Join to View Full Profile
75 Francis StBoston, MA 02115
Phone+1 617-732-5500
Dr. Mouw is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2011 - 2015- Mass General Brigham/Brigham and Women's HospitalInternship, Internal Medicine, 2010 - 2011
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2010
Certifications & Licensure
MA State Medical License 2012 - 2025
American Board of Radiology Radiation Oncology
Clinical Trials
- Avelumab and Radiation in Muscle-Invasive Bladder Cancer Start of enrollment: 2018 Dec 13
Publications & Presentations
PubMed
- Correction: EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.Allyson E Koyen, Matthew Z Madden, Dongkyoo Park, Elizabeth V Minten, Priya Kapoor-Vazirani
Oncogene. 2025-04-01 - Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer.Surish P Shanmugam, Yuzhen Zhou, Isabella Stelter, Timothy Hanlon, Raie T Bekele
Bladder Cancer. 2025-02-21 - Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma.Kevin K Zarrabi, Abhiraj Saxena, Kent W Mouw, Vadim S Koshkin, Terence Friedlander
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2025-01-01
Journal Articles
- Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 PandemicKent W Mouw, Paul L Nguyen, JAMA Oncology
Authored Content
- Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 PandemicAugust 2020
- Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 PandemicAugust 2020
Press Mentions
- Active Surveillance for Low-Risk Prostate Cancer in Black PatientsMay 22nd, 2019
Grant Support
- Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder CancerDANA-FARBER CANCER INST2024–2029
- Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder CancerDANA-FARBER CANCER INST2024–2029
- Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder CancerDANA-FARBER CANCER INST2022–2027
- Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder CancerDANA-FARBER CANCER INST2022–2027
- Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder CancerDANA-FARBER CANCER INST2022–2027
- Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder CancerDANA-FARBER CANCER INST2022–2027
- Investigating Interactions Between Radiation and Antibody-Drug Conjugates in Bladder CancerDANA-FARBER CANCER INST2024–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
